Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics

Bibliography

• Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10:428-38; 10.1038/nrd3405
   PubMed Web of Science ®Google Scholar
• Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Nat Acad Sci USA 1990;87:9868-72
   PubMed Web of Science ®Google Scholar
• Mosso A. Ueber den Kreislauf des Blutes im menschlichen Gehirn. 1881
   Google Scholar
• Roy CS, Sherrington CS. On the regulation of the blood-supply of the brain. J Physiol 1890;11:85-158
   PubMedGoogle Scholar
• Kwong KK, Belliveau JW, Chesler DA, Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Nat Acad Sci USA 1992;89:5675-9
   PubMed Web of Science ®Google Scholar
• Bandettini PA, Wong EC, Hinks RS, Time course EPI of human brain function during task activation. Magn Reson Med 1992;25:390-7
   PubMed Web of Science ®Google Scholar
• Frahm J, Bruhn H, Merbolt K, Hanicke W. Dynamic MR imaging of human brain oxygenation during rest and photic stimulation. Magn Reson Imag 1992;2:501-5
   Web of Science ®Google Scholar
• Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45
   PubMed Web of Science ®Google Scholar
• Large CH, Bison S, Sartori I, The efficacy of sodium channel blockers to prevent PCP-induced cognitive dysfunction in the rat: Potential for novel treatments for schizophrenia. J Pharmacol Exp Ther 2011;338(1):100-13
   PubMed Web of Science ®Google Scholar
• Chen CH, Ridler K, Suckling J, Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 2007;62:407-14
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Drabant EM, 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-34
   PubMed Web of Science ®Google Scholar
• Sheline YI, Barch DM, Donnelly JM, Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001;50:651-8
   PubMed Web of Science ®Google Scholar
• Fu CH, Williams SC, Cleare AJ, Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004;61:877-89
   PubMed Web of Science ®Google Scholar
• Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000;21:314-18
   PubMed Web of Science ®Google Scholar
• Javitt DC, Schoepp D, Kalivas PW, Translating Glutamate: from Pathophysiology to Treatment. Sci Transl Med 2011;3:102mr2
   PubMedGoogle Scholar
• Krystal JH, Karper LP, Seibyl JP, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
   PubMed Web of Science ®Google Scholar
• Luby ED, Cohen BD, Rosenbaum G, Study of a new schizophrenic-like drug: sernyl. Arch Neurol Psychiat 1959;81:363-9
   PubMedGoogle Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8
   PubMed Web of Science ®Google Scholar
• Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007;7:48-55
   PubMed Web of Science ®Google Scholar
• Tsai SJ. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med Sci Monit 2005;11:HY39-45; 7071 [pii]
   PubMed Web of Science ®Google Scholar
• Linderholm KR, Skogh E, Olsson SK, Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012;38(3):426-32
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Engberg G, Shimizu E, Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:767-9
   PubMed Web of Science ®Google Scholar
• Bendikov I, Nadri C, Amar S, A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 2007;90:41-51
   PubMed Web of Science ®Google Scholar
• Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H. Panizzutti Rr. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008;101:76-83
   PubMed Web of Science ®Google Scholar
• Do KQ, Cabungcal JH, Frank A, Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009;19:220-30
   PubMed Web of Science ®Google Scholar
• Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007;21:283-301
   PubMed Web of Science ®Google Scholar
• Gozzi A, Herdon H, Schwarz A, Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008;201:273-84
   PubMed Web of Science ®Google Scholar
• Gozzi A, Crestan V, Turrini G, Antagonism at serotonin 5-HT2A receptors modulates functional activity of fonto-hippocampal circuit. Psychopharmacology (Berl) 2010;209:37-50
   PubMed Web of Science ®Google Scholar
• Littlewood CL, Diana C, Dixon AL, Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006;32:1733-46
   PubMed Web of Science ®Google Scholar
• Gozzi A, Schwarz AJ, Reese T, Drug-anaesthetic interaction in phMRI: the case of the pyschotomimetic agent phencyclidine. Magn Reson Imag 2008;26:999-1006
   PubMed Web of Science ®Google Scholar
• Gozzi A, Large C, Schwarz A, differential effects of antipsychotic and glutamatergic agents on the phmri response to phencyclidine. Neuropsychopharmacology 2008;33:1690-703
   PubMed Web of Science ®Google Scholar
• Chin CL, Upadhyay J, Marek GJ, Awake rat pharmacological MRI as a translational pharmacodynamic biomarker: mGluR2/3 agonist modulation of ketamine-induced BOLD signals. J Pharmacol Exp Ther 2011;336(3):709-15
   PubMed Web of Science ®Google Scholar
• Risterucci C, Jeanneau K, Schoppenthau S, Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 2005;180:724-34
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation. Behav Brain Res 2012;230:291-8
   PubMed Web of Science ®Google Scholar
• Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005;5:101-6
   PubMed Web of Science ®Google Scholar
• Hodkinson DJ, de Groote C, McKie S, Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge. Br J Med Med Res 2012;2:373-85
   Google Scholar
• Roberts TJ, Williams SCR, Modo M. A pharmacological MRI assessment of dizocilpine (MK-801) in the 3-nitroproprionic acid-lesioned rat. Neurosci Lett 2008;444:42-7
   PubMed Web of Science ®Google Scholar
• Duncan GE, Moy SS, Knapp DJ, Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998;787:181-90
   PubMed Web of Science ®Google Scholar
• Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999;4:418-28
   PubMed Web of Science ®Google Scholar
• Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998;812:65-75
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 2000;22:400-12
   PubMed Web of Science ®Google Scholar
• Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005;93:1989-2001
   PubMed Web of Science ®Google Scholar
• Cavazzuti M, Porro CA, Biral GP, Ketamine effects on local cerebral blood flow and metabolism in the rat. J Cereb Blood Flow Metab 1987;7:806-11
   PubMed Web of Science ®Google Scholar
• Nakki R, Sharp FR, Sagar SM, Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res 1996;45:13-27
   PubMed Web of Science ®Google Scholar
• Deakin JFW, Lees J, McKie S, Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008;65:154-64
   PubMed Web of Science ®Google Scholar
• Langsjo JW, Kaisti KK, Aalto S, Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003;99:614-23
   PubMed Web of Science ®Google Scholar
• Silbersweig DA, Stern E, Frith C, A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995;378:176-9
   PubMed Web of Science ®Google Scholar
• Liddle PF, Lane CJ, Ngan E. Immediate effects of risperidone on cortico–striato–thalamic loops and the hippocampus. Br J Psychiatry 2000;177:402-7
   PubMed Web of Science ®Google Scholar
• Parellada E, Catafau AM, Bernardo M, Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res 1994;55:131-9
   PubMed Web of Science ®Google Scholar
• Ngan ETC, Lane CJ, Ruth TJ, Liddle PF. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J Neurol Neurosurg Psychiatry 2002;72:106-10
   PubMed Web of Science ®Google Scholar
• Soyka M, Koch W, Moller H, Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2005;255:308-12
   PubMed Web of Science ®Google Scholar
• Mitelman SA, Shihabuddin L, Brickman AM, Volume of the cingulate and outcome in schizophrenia. Schizophr Res 2005;72:91-108
   PubMed Web of Science ®Google Scholar
• Kircher TT, Thienel R. Functional brain imaging of symptoms and cognition in schizophrenia. Prog Brain Res 2005;150:299-308
   PubMed Web of Science ®Google Scholar
• Clinton SM, Meador-Woodruff JH. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 2004;69:237-53
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia–therapeutic implications. Biol Psychiatry 1999;46:1388-95
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009;12:468-78
   PubMed Web of Science ®Google Scholar
• Depoortere R, Dargazanli G, Estenne-Bouhtou G, Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005;30:1963-85
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Singh N, Elander J, Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012;37:1036-46
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010;16:522-37; CPD-Guochuan E. Tsai (Albert Adell) [pii]
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Bures M, Johnson MP, Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005;4:131-44
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-97
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-52
   PubMed Web of Science ®Google Scholar
• Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999;291:161-70
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Marek GJ. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 2002;1:215-25
   PubMed Web of Science ®Google Scholar
• Krystal JH, Abi-Saab W, Perry E, Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005;179:303-9
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Zhang L, Williams JE, LY2140023 monohydrate: an agonist at the mglu2/3 receptor for the Treatment of Schizophrenia. Schizophr Res 2010;117:379
   Web of Science ®Google Scholar
• Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 2005;179:336-48
   PubMed Web of Science ®Google Scholar
• Gaisler-Salomon I, Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 2003;V166:333-42
   Google Scholar
• Linn S, Negi S, Gerum V, Javitt C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology 2003;V169:234-9
   Google Scholar
• Qiao H, Noda Y, Kamei H, Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001;12:11-15
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Adler CM, Kennison SD, Clozapine Blunts N-Methyl–Aspartate Antagonist-Induced Psychosis: a Study with Ketamine. Biol Psychiatry 1997;42:664-8
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Martinez D, Kochan LD, NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002;43:19-29
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996(Suppl):23-31
   Google Scholar
• Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 2001;11:543-50
   PubMed Web of Science ®Google Scholar
• Dawson N, Morris BJ, Pratt JA. Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems. Schizophr Bull 2011; sbr144 [pii];10.1093/schbul/sbr144 [doi]
   PubMed Web of Science ®Google Scholar
• Bifone A, Gozzi A, Schwarz AJ. Functional connectivity in the rat brain: a complex network approach. Magn Reson Imag 2010;28:1200-9
   PubMed Web of Science ®Google Scholar
• Schwarz AJ, Gozzi A, Reese T, Bifone A. Functional connectivity in the pharmacologically activated brain: resolving networks of correlated responses to d-amphetamine. Magn Reson Med 2007;57:704-13
   PubMed Web of Science ®Google Scholar
• Schwarz AJ, Gozzi A, Bifone A. Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI. Neuroimage 2009;47:302-11
   PubMed Web of Science ®Google Scholar
• Lu H, Zou Q, Gu H, Rat brains also have a default mode network. PNAS 2012;109:3979-84
   PubMed Web of Science ®Google Scholar
• Schwarz AJ, Gozzi A, Chessa A, Bifone A. Voxel scale complex networks of functional connectivity in the rat brain: neurochemical state dependence of global and local topological properties. Comput Math Methods Med 2012;2012:Article ID 615709
   Google Scholar
• Schwarz AJ, Gozzi A, Bifone A. Community structure and modularity in networks of correlated brain activity. Magn Reson Imaging 2008;26:914-20
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11:642-51
   PubMed Web of Science ®Google Scholar
• Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27:11496-500
   PubMed Web of Science ®Google Scholar
• Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001;11:569-77
   PubMed Web of Science ®Google Scholar